Dexcom Inc reports results for the quarter ended September 30 - Earnings Summary

By Reuters News
  • Dexcom Inc reported quarterly adjusted earnings of 73 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 61 cents. The mean expectation of twenty five analysts for the quarter was for earnings of 67 cents per share. Wall Street expected results to range from 63 cents to 72 cents per share.

  • Revenue rose 11.2% to $1.34 billion from a year ago; analysts expected $1.33 billion.

  • Dexcom Inc's reported EPS for the quarter was 72 cents​.

  • The company reported quarterly net income of $275.1 million.

  • Dexcom Inc shares had fallen by 8.9% this quarter and gained 18.5% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had risen by about 0.3% in the last three months.​

  • In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

  • Wall Street's median 12-month price target for Dexcom Inc is $95.00, about 15.9% above its last closing price of $79.93

This summary was machine generated from LSEG data October 29 at 10:25 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Sep. 30 2026

0.67

0.73

Beat

Jun. 30 2026

0.61

0.70

Beat

Mar. 31 2026

0.47

0.56

Beat

Dec. 31 2025

0.65

0.45

Missed

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk